1stOncology™: Cancer Intelligence Service – Page 11254 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020

On September 1, 2020 Harbour BioMed (HBM), a global, clinical-stage, innovative biopharmaceutical company, reported its newly discovered novel anti-human CCR8 mAbs (HBM1022) at the 16th PEGS Boston Summit (Press release, Harbour BioMed, SEP 1, 2020, View Source [SID1234564252]). HBM1022 was designed to target C-C chemokine receptor type 8 (CCR8), an extremely challenging G-protein coupled receptor (GPCR) with limited success in generating a cross-reactive antibodies in the past (cynomolgus and human). The poster was presented through a voice-over presentation at the 16th PEGS Boston Summit (from August 31 to September 4, 2020).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

CCR8 is selectively up-regulated in tumor resident Treg cells in multiple solid tumors, but rarely observed on Treg cells in peripheral blood mononuclear cells (PBMCs) or other normal organs. High expression of CCR8 on Treg cells was first found to be associated with poor prognosis in breast cancer patients. These results suggest CCR8 could potentially be a promising therapeutic target.

HBM used a combination of next generation technologies including Single B Cell Technology with advanced phage display and hybridoma platforms to successfully develop the anti-CCR8 monoclonal antibody. It selectively targeted and depleted a subpopulation of tumor resident CCR8+ Tregs in the tumor microenvironment resulting in tumor growth inhibition, both as a single agent as well as in combination with anti-PD-1 antibody in preclinical setting. Furthermore, this antibody blocked the binding of CCL1 to CCR8 thereby inhibiting CCL1-induced suppressive function of TIL-Tregs.

"The ability to modulate the tumor micro-environment with a target like CCR8, either by itself or in combination with other molecules is an extremely promising approach. We are excited to develop this candidate further into a therapy that could address multiple tumor types in the future," Dr. Jingsong Wang said, the Founder, Chairman, and CEO of Harbour BioMed. "The success of generating antibodies against a difficult GPCR target further demonstrates the power and efficiency of HBM’s antibody discovery platforms," he added.

Poster Title:

Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates for Next Generation Cancer Immunotherapy

Please click the link below for the poster: View Source;sortByFields[0]=createdAt&sortByOrders[0]=-1

Legend Biotech to Participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference

On September 1, 2020 Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, reported that it will participate in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference on Tuesday, September 15th (Press release, Legend Biotech, SEP 1, 2020, View Source [SID1234564251]). Frank Zhang, Chairman and Chief Executive Officer, and Ying Huang, Chief Financial Officer, will represent the Company in a session scheduled at 11:00 a.m. (Eastern Time).

This webcast will be available to investors and other interested parties by accessing the Legend Biotech website at View Source

NeuClone Discloses Two Biosimilars Referencing Opdivo® and Keytruda®

On September 1, 2020 NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company developing high-quality biosimilar products, reported two additional biosimilars in active development (Press release, NeuClone Pharmaceuticals, SEP 1, 2020, View Source [SID1234564250]). The products are biosimilar candidates referencing Opdivo (nivolumab) and Keytruda (pembrolizumab

These biosimilars reference two antibody products that block the PD-1 immune checkpoint inhibitor pathway and their use has dramatically improved the prognosis of patients across multiple oncology settings. Combined global sales of the two reference products in 2019 were US$19.2 billion and are forecast to reach over US$32 billion in 2024.1

"These two medicines have helped reshape previous standard-of-care approaches for many cancer patients" stated Dr Noelle Sunstrom, CEO and Founder of NeuClone. "Providing affordable biosimilar alternatives is crucial to allow many more patients around the world access to these life changing treatments."

The biosimilar candidates are in the advanced stages of pre-clinical development and are being co-developed by NeuClone and its strategic manufacturing partner, Serum Institute of India (Serum Institute).

"Serum Institute is committed to co-developing a broad range of biosimilars with NeuClone to expand global market access of these valuable medicines to under-served cancer patients" stated Mr Adar Poonawalla, CEO of Serum Institute.

The disclosure of these biosimilars demonstrates NeuClone’s unique ability to develop multiple biosimilars simultaneously through its proven NeuMAX platform. In addition to these two products, NeuClone and Serum Institute are developing eight other biosimilars, including clinical-stage candidates referencing Stelara (ustekinumab) and Herceptin (trastuzumab).

Shattuck Labs to Present at PEGS Summit 2020

On September 1, 2020 Shattuck Labs, Inc. ("Shattuck"), an innovative clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC) platform to develop an entirely new class of biologic medicines for the treatment of cancer and autoimmune disease, reported its presentation at the PEGS Summit 2020 being held virtually August 31 – September 4, 2020 (Press release, Shattuck Labs, SEP 1, 2020, View Source [SID1234564249]).

Presentation Details
Presentation Title: CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity
Presentation Subtitle: Preclinical and Clinical Development of SL-172154
Date/Time: September 4 at 11:10 a.m. EDT
Presenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer
Location: https://www.pegsummit.com/

Biognosys announces Nature Communications publication in collaboration with ETH Zurich, Bayer, and BASF

On September 1, 2020 Biognosys reported the publication of new research findings in Nature Communications on the utility of its LiP technology and workflow for drug target identification (Press release, Biognosys, SEP 1, 2020, View Source [SID1234564247]). The publication, entitled "A Machine-Learning-Based Chemoproteomic Approach to Identify Drug Targets and Binding Sites in Complex Proteomes", is co-authored by collaborators from ETH Zurich, Biognosys, Bayer and BASF.

In this publication, we present a novel chemoproteomic workflow combining LiP and machine learning-based data analysis. This next-generation proteomics approach enables the identification of small molecule drug targets in complex proteomes and the analysis of their binding properties across species and drug target classes.

Oliver Rinner, Chief Executive Officer of Biognosys, comments: "Understanding a compound’s mechanism of action remains a major challenge in drug development. This publication is a testimony to our commitment to support our pharma and biotech partners with unique applications for more efficient drug discovery."

Lukas Reiter, Chief Technology Officer, states: "Biognosys’ quantitative proteomics technology based on data independent acquisition (DIA) is a perfect fit for the LiP technology. This combined workflow enabled us to develop a target deconvolution approach for human cell lines."

Prof. Dr. Paola Picotti, Associate Professor in Molecular Systems Biology and head of the Picotti group at ETH Zurich, and Scientific Advisor for Biognosys, says: "With the LiP approach, we can now also identify compound-binding in very complex mammalian cell systems with high confidence. In addition, we get information on binding affinity, which helps us to prioritize targets for follow-up studies."

Thomas Knobloch, Laboratory Manager at Bayer CropScience, adds: "The LiP technology is a very valuable tool to identify target and off-target of novel compounds whatever the organism and to support the process of target deconvolution in early phase research."

Earlier this year, Biognosys published research findings demonstrating the utility of LiP-based proteomics for drug discovery at the US Human Proteome (HUPO) Conference and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting.

About Limited Proteolysis (LiP)

The Limited Proteolysis technology coupled to next-generation quantitative mass spectrometry is a novel approach that enables the unbiased and proteome-wide profiling of protein changes resulting from a variety of stimuli such as heat shock, protein-protein interactions, compound binding, and posttranslational modifications.

Invented by the group of Prof. Paola Picotti at ETH Zurich, this patented technology is exclusively licensed to and co-developed by Biognosys to support pharma and biotech partners with contract research services for drug discovery and development. Biognosys already offers a LiP-technology based target deconvolution application and is developing additional, machine-learning-based applications for target validation.